Brainstorm Cell Therapeutics Inc. · OTC:BCLI
Brainstorm Cell Therapeutics — Corporate Update (March 2018)
20 slides from Brainstorm Cell Therapeutics's corporate update, Mar 8, 2018
Slide 1: BrainStorm Cell Therapeutics Company Update
BrainStorm Cell Prepared Therapeutics NASDAQ: BCLI COMPANY UPDATE Chaim Lebovits, CEO March 8, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by su
Slide 3: 2017-2018 Progress
2017-2018 Progress Non-dilutive Manufacturing funding Phase 3 US Strengthened ALS study executive launch team
Slide 4: Leveraging Core Company Capabilities
Leveraging Core Company Capabilities Manufacturing excellence Strong Science • NurOwn Cryopreservation • Cell and disease biology • Manufacturing Capabilities • Industry CNS experience Strategic Partnerships Patient Focus • California Institute for • Patient Advocacy Leadership Regenerative Medicine
Slide 5: NurOwn Technology
NurOwn® Technology Time to MSC cryopreserved 21 days product Time from cryopreservation 7 days to final product Israel GMP manufacturing January 2018 certification 5
Slide 6: NurOwn Product Characteristics
NurOwn® Product Characteristics VEGF HGF LIF CRP MCP-1 SDF-1 1000 600 18 1600 50 250 * ** *** *** ** 900 16 ↓Neuro- 1400 45 800 700 500 ↑Neuroprotection 14 inflammation 1200 40 35 200 400 12 1000 600 30 150 pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml 10 500 300 800 25 NurOwn ® 400 300 200 8 6 600 400 20 15
Slide 7: NurOwn successfully evaluated in preclinical models of neurodegenerative disease
NurOwn® successfully Parkinson’s evaluated in preclinical Disease models of neurodegenerative disease Huntington’s Multiple Disease Sclerosis ALS 7 Autism
Slide 8: High Unmet Need Across Neurodegenerative Disorders
High Unmet Need Across Neurodegenerative Disorders Amyotrophic Parkinson’s Progressive Alzheimer’s Huntington Autism Spectrum Lateral Disease Multiple Disease ’s Disease Disorder (ASD) Sclerosis (PD) Sclerosis (MS) (AD) (HD) (ALS) Global patients 220,000 10,000,000 1,250,000 47,000,000 300,000 35,00
Slide 9: Global Prevalence of ALS Increasing
Global Prevalence of ALS Increasing (2015-2040) Nature Communications 2016
Slide 10: Notice of Allowance to Include Parkinson's Disease
Rich IP portfolio- Strengthened November 2017 with US Notice of Allowance to Include Parkinson’s Disease Allowed Granted Patent Name/ Int. App. No. Pending Jurisdictions Expiry Date Jurisdictions Jurisdictions ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF US Europe, US 2030 CNS
Slide 11: NurOwn Regulatory Status
NurOwn® Regulatory Status Orphan Drug Fast Track Designation Designation • US and EU • US 11
Slide 12: 2017 P&L Report
2017 P&L Report 2017 2016 Operating expenses Research and development, net 977 (*) 2,250 General and administrative 4,022 2,833 Operating loss 4,999 5,083 Financial income 47 101 Net loss 4,952 4,982 Basic and diluted net loss per share from 0.26 0.27 continuing operations (*) Research and developme
Slide 13: 2017 P&L Report
2017 P&L Report 2017 2016 Operating expenses Research and development, net 977 (*) 2,250 General and administrative 4,022 2,833 Operating loss 4,999 5,083 Financial income 47 101 Net loss 4,952 4,982 Basic and diluted net loss per share from 0.26 0.27 continuing operations (*) Research and developme
Slide 14: 2017 P&L Report
2017 P&L Report 2017 2016 Operating expenses Research and development, net 977 (*) 2,250 General and administrative 4,022 2,833 Operating loss 4,999 5,083 Financial income 47 101 Net loss 4,952 4,982 Basic and diluted net loss per share from 0.26 0.27 continuing operations (*) Research and developme
Slide 15: 2017 Balance Sheet
2017 Balance Sheet Dec. 31st, 2017 Dec. 31st, 2016 Current Assets Cash and Cash equivalents 2,483 547 Short-term deposit 5,273 9,443 Account receivable 672 306 Prepaid expenses 1,195 148 Total Current Assets 9,623 10,444 Long-Term Assets 1,800 322 Total Assets 11,423 10,766 15
Slide 16: NurOwn ALS Development- Update
NurOwn® ALS Development- Update NurOwn ALS ALS ALS 2007 Early 2010 Phase 1/2a 2014 US Phase 2 2017+ US Phase 3 Development Repeat dosing Rapid progressors 200 48 # of Study Participants 26 16 Phase 1/2 Phase 2 Phase 3
Slide 17: NurOwn Phase 3 Randomized ALS Study (BCT-002-US)- Status and Timelines
® NurOwn Phase 3 Randomized ALS Study* (BCT-002-US)- Status and Timelines 6 leading US Study Study design Study Status ALS sites Completion 3 bimonthly doses Total study duration Mass General; U 200 patients 11.5 months 1:1 randomization Mass; Mayo; CPMC; Enrollment to be Cedars-Sinai; UCI 7 months
Slide 18: Recent additions to Brainstorm's Board of Directors
Recent additions to Brainstorm’s Board of Directors Arturo Arraya MA, BS, MBA • Formerly Vice President and Head of Global Commercial for Novartis’ Cell and Gene Therapies Unit June S. Almenoff MD PhD • Formerly President and CMO of Furiex Pharmaceuticals. Tony Polverino PhD • CSO Kite Pharmaceutica
Slide 19: Management Team
Management Team Chaim Lebovits Yael Gothelf PhD. President and CEO VP, Scientific and Regulatory Affairs Uri Yablonka Ralph Kern, MD, MHSc. SVP, Chief Business Officer COO and CMO Eyal Rubin Yossef Levy PhD. EVP, CFO VP, Cell Production Mary Kay Turner VP, Patient Advocacy and Revital Aricha PhD. Go
Slide 20: Thank You
BrainStorm Cell Therapeutics NASDAQ: BCLI Thank You
BrainStorm Cell Therapeutics — Corporate Update (March 2018) on 6ix